Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter and Full Year 2012 Financial Results on

Tengion to Host Conference Call to Provide a Business Update and Report Fourth
        Quarter and Full Year 2012 Financial Results on March 18, 2013

PR Newswire

WINSTON-SALEM, N.C., March 11, 2013

WINSTON-SALEM, N.C., March 11, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB:
TNGN), a leader in regenerative medicine, today announced it will host a
conference call and live audio webcast on Monday, March 18, 2013, at 9:00 a.m.
EDT to provide a business update and discuss its fourth quarter and full year
2012 financial results.

To participate in the call, please dial 1-866-543-6403 (domestic) or
1-617-213-8896 (international) and reference access code 98136968. The
conference call can be accessed from the Investors & News section of the
Company's website or directly at http://www.media-server.com/m/p/pfbbcfmc.

A replay of the call will be available one hour after the end of the
conference on March 18, 2013 until 11:59 p.m. EDT on March 25, 2013. To access
the replay, please dial 1-888-286-8010 (domestic) or 1-617-801-6888
(international) and reference the access code 69683056. The archived webcast
will be available for 30 days on the Company's website at www.tengion.com.

About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on
developing its Organ Regeneration Platform™ to harness the intrinsic
regenerative pathways of the body to regenerate a range of native-like organs
and tissues with the goal of delaying or eliminating the need for chronic
disease therapies, organ transplantation, and the administration of
anti-rejection medications. An initial clinical trial is ongoing for the
Company's most advanced product candidate, the Neo-Urinary Conduit™, an
autologous implant that is intended to catalyze regeneration of native-like
urinary tissue for bladder cancer patients requiring a urinary diversion
following bladder removal. The Company's lead preclinical candidate is the
Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney
transplantation by increasing renal function in patients with advanced chronic
kidney disease. Tengion has worldwide rights to its product candidates.







SOURCE Tengion, Inc.

Website: http://www.tengion.com
Contact: Investor and Media, Brian Davis, brian.davis@tengion.com,
+1-336-201-0155